Skip to content

Avantor AVTR VWR Distribution & Services — Net Sales

Other segment segments

Bioscience & Medtech Products
$431.4M

Similar metrics at other companies

West Pharmaceutical Services logo
WSTWest Vantage — Net Sales
$150.6M+11.6%
Terex logo
TEXSV — Net Sales
$436M
Applied Industrial Technologies logo
AITService Center — Net Sales
$806.02M+5.7%
GLW
GLWLife Science Products — Net Sales
$228M0.0%
Applied Industrial Technologies logo
AITService Center Segment — Net Sales
$754.31M-1.4%
Advanced Drainage Systems logo
WMSWastewater — Net Sales
$178.64M+13.4%

Other financials

Income statement

See full
Revenue$1.6B0.0%
Gross profit$500.7M-6.4%
Operating income$99.5M-32.5%
Net income$43.3M-32.9%
EPS (diluted)$0.06-33.3%

Balance sheet

See full
Cash & equivalents$282.2M-11.4%
Total debt$3.8B-7.1%
Total equity$5.6B-8.4%
Total assets$11.7B-5.4%

Cash flow

See full
Operating cash flow$58.7M-46.3%
CapEx$33.5M+19.6%
Free cash flow$25.2M-69.0%

Valuation

See full
Market cap$6.54B-52.0%
Enterprise value$10.07B-40.4%
P/S-1.0×

Profitability

See full
Gross margin32.1%-1.4pp
Operating margin4%-5.2pp
Net margin-9.2%-19.9pp
FCF margin6.7%-3.3pp

Returns & leverage

See full
Return on equity-10.3%-22.8pp
Debt / equity0.7×0.0×
Current ratio1.8×+0.6×

Where this comes from

Reported directly by Avantor in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Avantor’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avantor's vwr distribution & services — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avantor's VWR distribution & services — net sales?
Avantor (AVTR) reported VWR distribution & services — net sales of $1.15B in Q1 2026.
What does VWR distribution & services — net sales mean?
This metric represents the total revenue generated from the sale of products and services within the VWR distribution business segment. It reflects the company's ability to monetize its supply chain, laboratory equipment, and specialty procurement offerings to biopharma and industrial customers. Growth in this figure indicates successful market penetration and demand for the segment's portfolio.